A share price of Avidity Biosciences Inc [RNA] is currently trading at $31.27, up 6.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RNA shares have gain 9.87% over the last week, with a monthly amount drifted -13.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on June 24, 2025, when Bernstein initiated its Outperform rating and assigned the stock a price target of $50. Previously, Wolfe Research started tracking the stock with Outperform rating on June 17, 2025, and set its price target to $55. On June 11, 2025, Raymond James initiated with a Strong Buy rating and assigned a price target of $65 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $70 on March 13, 2025. BMO Capital Markets initiated its recommendation with a Outperform and recommended $72 as its price target on March 12, 2025. Scotiabank started tracking with a Sector Outperform rating for this stock on March 07, 2025, and assigned it a price target of $70. In a note dated December 20, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $72 on this stock.
Avidity Biosciences Inc experienced fluctuations in its stock price throughout the past year between $21.51 and $56.00. Currently, Wall Street analysts expect the stock to reach $54.5 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $31.27 at the most recent close of the market. An investor can expect a potential return of 74.29% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Trailing Twelve Months sales for Avidity Biosciences Inc [NASDAQ:RNA] were 8.93M which represents -55.60% decline. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.53%, Pretax Profit Margin comes in at -41.36%, and Net Profit Margin reading is -41.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.27 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.87 points at the first support level, and at 28.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.13, and for the 2nd resistance point, it is at 32.98.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avidity Biosciences Inc [NASDAQ:RNA] is 16.91. Further, the Quick Ratio stands at 16.91, while the Cash Ratio is 3.0. Considering the valuation of this stock, the price to sales ratio is 422.09, the price to book ratio is 2.84.
Transactions by insiders
Recent insider trading involved Gallagher Kathleen P., Chief Program Officer, that happened on Jun 17 ’25 when 911.0 shares were sold. Officer, KATHLEEN GALLAGHER completed a deal on Jun 17 ’25 to buy 911.0 shares. Meanwhile, Chief Scientific Officer Flanagan W. Michael sold 20000.0 shares on Jun 11 ’25.
